These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25062564)

  • 1. Preserved adrenal function in fully PCSK9-deficient subject.
    Cariou B; Benoit I; Le May C
    Int J Cardiol; 2014 Sep; 176(2):499-500. PubMed ID: 25062564
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency.
    Jänis MT; Tarasov K; Ta HX; Suoniemi M; Ekroos K; Hurme R; Lehtimäki T; Päivä H; Kleber ME; März W; Prat A; Seidah NG; Laaksonen R
    Atherosclerosis; 2013 Jun; 228(2):380-5. PubMed ID: 23623011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics: a gene of rare effect.
    Hall SS
    Nature; 2013 Apr; 496(7444):152-5. PubMed ID: 23579660
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the first PCSK9 gain of function homozygote.
    Alves AC; Etxebarria A; Medeiros AM; Benito-Vicente A; Thedrez A; Passard M; Croyal M; Martin C; Lambert G; Bourbon M
    J Am Coll Cardiol; 2015 Nov; 66(19):2152-2154. PubMed ID: 26541928
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conversation with Helen Hobbs.
    Hobbs H; Neill US
    J Clin Invest; 2015 Oct; 125(10):3725-6. PubMed ID: 26426073
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibition--a new thrust in the prevention of heart disease: genetics does it again.
    Roberts R
    Can J Cardiol; 2013 Aug; 29(8):899-901. PubMed ID: 23809538
    [No Abstract]   [Full Text] [Related]  

  • 11. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family.
    Ruotolo A; Di Taranto MD; D'Agostino MN; Marotta G; Gentile M; Nunziata M; Sodano M; Di Noto R; Del Vecchio L; Rubba P; Fortunato G
    Clin Chem Lab Med; 2014 Aug; 52(8):e175-8. PubMed ID: 24607922
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
    Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
    J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.
    Fazio S; Tavori H
    Circ Res; 2014 Aug; 115(5):472-4. PubMed ID: 25124321
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches].
    Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C
    Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189
    [No Abstract]   [Full Text] [Related]  

  • 18. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.
    Berger JM; Vaillant N; Le May C; Calderon C; Brégeon J; Prieur X; Hadchouel J; Loirand G; Cariou B
    Atherosclerosis; 2015 Mar; 239(1):252-9. PubMed ID: 25621930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.